Human Circadian Sensitivity to Very Short Light Pulses

Circadian Rhythm Disorders Clinical Trial

Official title:

Human Circadian Sensitivity to Very Short Light Pulses

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01330992
• Other study ID #: NIH-RC2-HL101340
• Status: Completed
• Phase: N/A
• First received: April 1, 2011
• Last updated: August 19, 2011
• Start date: December 2009
• Est. completion date: August 2011

Study information

• Verified date: August 2011
• Source: Brigham and Women's Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The mammalian eye serves both visual and non-image-forming functions. New information about the non-image-forming anatomy and physiology of the eye has revealed effects of ocular light stimuli on human circadian rhythms, melatonin suppression, heart rate, pupillary reflexes, cognitive performance, alertness and sleep. The results of the proposed work can be used to make predictions about the effects of light, to make recommendations involving exposure to or avoidance of light, and to design environmental lighting, resulting in improved health and alertness and decreased errors and accidents.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: August 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers

Exclusion Criteria:

• No medications

• No eye disease

• No sleep disorders

• No psychiatric disorders

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Chronobiology Disorders
• Circadian Rhythm Disorders

Intervention

Other:
• Ocular light or darkness exposure
Ocular light or darkness exposure

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Circadian Phase (hours)	Circadian phase (hours) measured before and after intervention	Before and after intervention (day 1)	No